Business
PAVmed Provides Business Update and Second Quarter Financial Results
EsoGuard® test volume continues to grow as Lucid makes strides with commercial expansion and additional supporting data Veris Health prepares to launch the
About this update from Pavmed Inc.
[{"type":"text","content":"EsoGuard® test volume continues to grow as Lucid makes strides with commercial expansion and additional supporting data\nVeris Health prepares to launch the next generation of the Veris Cancer Care Platform along with strategic initiatives to develop a biopharma companion digital module to support new cancer therapeutics and to seek FDA clearance as a SaMD \nConference call and webcast to be held tomorrow, August 16th at 8:30 AM EST\nNEW YORK, Aug. 15, 2023 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM, PAVMZ) (\"PAVmed\" or the \"Company\"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ: LUCD) (\"Lucid\") and Veris Health Inc. (\"Veris\"), and presented financial results for the Company for the three and six months ended June 30, 2023.\n\n \n \n \n \n \n \n\n \nConference Call and Webcast\nThe webcast will take place on Wednesday, August 16, 2023, at 8:30 AM and is accessible in the investor relations section of the Company's website at pavmed.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-833-816-1419 and international listeners should dial 412-317-0512. All listeners should provide the operator with the conference call name \"PAVmed Business Update\" to join.\nFollowing the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at pavmed.com.\nBusiness Update Highlights\n\"Both Lucid and Veris have strong momentum as we enter the second half of the year and we look forward to both delivering on their commercial and strategic plans in the coming quarters,\" said Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer.\n\"The Veris Cancer Care Platform is having a meaningful impact on the care of enrolled cancer patients at early adopter practices, as we have focused on optimizing customer acceptance and validation together with customization and integration with their respective EHR platforms. A next generation version of the platform incorporating early feedback will launch later this year. Gary Manning, President of Veris Health, has accelerated our progress, completing a detailed review of the software and ...